Q4 & FY 2019 SPAC IPO Auditor League Tables
Below are the newly released SPAC Auditor League Tables for both the Fourth-Quarter, as well as Full Year 2019. As you can see below, the Auditor’s League is essentially a two-horse race. Marcum LLP and WithumSmith+Brown (“Withum”) consistently dominate the category, leaving little room for competition.
For Full Year 2019, Marcum managed 29 auditing assignments to Withum’s 21, with Grant Thornton clocking in at four total. KPMG, BPM, Maloney Bailey, RBSM and UHY, all worked on one SPAC each.
Looking at both the Fourth Quarter as well as Full Year 2019, Marcum led the league in both volume and deal count with $6.6 billion and 29 SPACs, respectively. However, Withum was not far behind at $5.2 billion and 21 SPACs. However, you will notice that Withum had a bigger average deal size for 2019 ($245.9 million to Marcum’s $229.3 million), due to Withum being the auditor on a greater number of larger sized deals. Withum’s smallest sized SPAC was Amplitude Healthcare’s $100 million IPO (AHCO), whereas Marcum’s smallest IPO was Orisun Acquisition Corp.’s $44 million (ORSN).
Grant Thornton LP, ranked third and had roughly the same average deal size as Withum ($246.1 million) with four auditing assignments.
It was a strong year for Marcum and Withum, clearly the leaders in the SPAC auditing category. And given the success of SPACs in 2019, it will be interesting to see if any of the other auditors make a push in 2020 to give these leaders some competition. SPAC experience counts though, and these two auditors have it in spades.
You can find all of the published League Tables by clicking here.
Ranked by Volume
(All data is sort-able using the arrow keys located in the header cells)
FY 2019
| Rank | Auditor | Volume ($mm) | Deal Count (Total) | Avg Size ($mm) | % Mkt Share |
|---|---|---|---|---|---|
| 1 | Marcum LLP | 6,648.8 | 29 | 229.3 | 48.9% |
| 2 | WithumSmith+Brown, PC | 5,164.6 | 21 | 245.9 | 38.0% |
| 3 | Grant Thornton LP | 984.4 | 4 | 246.1 | 7.2% |
| 4 | KPMG LLP | 400.0 | 1 | 400.0 | 2.9% |
| 5 | BPM LLP | 172.5 | 1 | 172.5 | 1.3% |
| 6 | Malone Bailey LLP | 115.0 | 1 | 115.0 | 0.8% |
| 7 | RBSM LLP | 57.5 | 1 | 57.5 | 0.4% |
| 8 | UHY LLP | 57.5 | 1 | 57.5 | 0.4% |
Q4 2019
| Rank | Auditor | Volume ($mm) | Deal Count (Total) | Avg Size ($mm) | % Mkt Share |
|---|---|---|---|---|---|
| 1 | Marcum LLP | 1,788.8 | 9 | 198.8 | 52.9% |
| 2 | WithumSmith+Brown, PC | 1,333.0 | 7 | 190.4 | 39.4% |
| 3 | Grant Thornton LP | 258.8 | 1 | 258.8 | 7.7% |
Source: SPACInsider, Ranked by volume
Terms Tracker for the Week Ending March 24, 2023 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. While this week was relatively quiet on the filings front, we did see March’s second SPAC IPO price with Oak Woods Acquisition Corp’s $50 million...
Latest Non-Redemption Agreements: ExcelFin Acquisition Corp. ExcelFin Acquisition Corp. (XFIN) Adds Non-Redemption Agreement In connection with the special meeting of stockholders of ExcelFin Acquisition Corp. (NASDAQ:XFIN) to extend its completion deadline from April 25, 2023 to October 25, 2023, the company and its sponsor, ExcelFin SPAC LLC, entered into a non-redemption agreement with an unaffiliated third party....
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Latest SPAC News: Momentus SPAC backers accused of deliberately engineering a catastrophic deal Momentus SPAC Backers Accused of Hiding Disastrous Deal’s Flaws A Momentus Inc. (NASDAQ:MNTS) investor sued backers of its blank-check merger with a shell company,...
DiamondHead Holdings Corp. (NASDAQ:DHHC) announced in an 8-K this morning that its shareholders approved its combination with Great Southern Homes at a special meeting March 23. Only 109,426 shares were redeemed in the connection with the vote, but DiamondHead has seen about 87% redemptions in total across all previous votes, leaving it with about $43.9...
Graf Acquisition Corp. IV (NYSE:GFOR) announced that it has signed a non-binding letter of intent to combine with clinical-stage biopharma company NKGen. This announcement is not a pure teaser as Graf IV is not facing an imminent extension vote and currently has until May 25 on its clock. It does, however, signal something of a...